Literature DB >> 3326987

The iatrogenic leukaemias induced by radio- and/or chemotherapy.

Y Najean1.   

Abstract

A short review, limited to recently published series of data, has been compiled on the 'therapy-induced' secondary malignancies. Their frequency, peak of incidence, haematological and clinical criteria, the influence of age, treated primary disease, choice of drug(s) and modality of prescription and the role of genetic and environmental factors are analyzed. The risk varies between 0.6 and 20.5% after different treatment forms. Some suggestions for the choice of treatment of chronic malignant disorders, and for the design of future epidemiological studies are given.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3326987     DOI: 10.1007/bf02934521

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  62 in total

1.  Childhood leukaemia in the West Berkshire and Basingstoke and North Hampshire District Health Authorities in relation to nuclear establishments in the vicinity.

Authors:  E Roman; V Beral; L Carpenter; A Watson; C Barton; H Ryder; D L Aston
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-07

2.  Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.

Authors:  W P Vaughan; J E Karp; P J Burke
Journal:  J Clin Oncol       Date:  1983-03       Impact factor: 44.544

3.  The genetic implications of long-term survival of childhood cancer. A conceptual framework.

Authors:  L C Strong; W R Williams
Journal:  Am J Pediatr Hematol Oncol       Date:  1987

4.  Therapy-related leukemia: a panmyelosis.

Authors:  K Foucar; R W McKenna; C D Bloomfield; T K Bowers; R D Brunning
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

5.  Prolonged survival in patients with treatment-related leukemia.

Authors:  E C Kingsley; B G Durie
Journal:  Scand J Haematol       Date:  1986-08

6.  Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders.

Authors:  M M Le Beau; C A Westbrook; M O Diaz; R A Larson; J D Rowley; J C Gasson; D W Golde; C J Sherr
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

7.  Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience.

Authors:  A J Koletsky; J R Bertino; L R Farber; L R Prosnitz; D S Kapp; D Fischer; C S Portlock
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

8.  Therapy-related preleukemic syndrome.

Authors:  R L Anderson; G C Bagby; K Richert-Boe; R E Magenis; R D Koler
Journal:  Cancer       Date:  1981-04-01       Impact factor: 6.860

9.  Cancer following medical irradiation.

Authors:  J D Boice
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

10.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors: 
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

View more
  1 in total

Review 1.  Chemoprotection of normal tissues by transfer of drug resistance genes.

Authors:  J A Rafferty; I Hickson; N Chinnasamy; L S Lashford; G P Margison; T M Dexter; L J Fairbairn
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.